ArticleCureus2025
The Impact of Volume Removal by Hemodialysis on Elevated NT-proBNP Levels in Patients With Hypervolemia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effect of hemodialysis on high-sensitivity cardiac troponin T levels in patients with hypervolemia.Frontiers in nephrology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION AND
aimN-terminal pro-brain-type natriuretic peptide (NT-proBNP) is highly sensitive and specific for the diagnosis of congestive heart failure (CHF). Most patients with end-stage kidney disease (ESKD) on renal replacement therapy have an elevated NT-proBNP plasma level due to volume gain between dialysis sessions. Measuring plasma NT-proBNP levels before and after hemodialysis (HD) in patients hospitalized with volume expansion is a common practice. This study aimed to determine the clinical value of repeated plasma NT-proBNP measurements in patients with ESKD or acute kidney injury (AKI) requiring HD and to study the effect of volume removal via HD on NT-proBNP plasma levels.
methodsWe conducted a retrospective analysis of patients admitted to two community hospitals over a three-year period (from January 1, 2020, to December 31, 2022). Patients with AKI requiring HD or ESKD were screened if they had an admission diagnosis of volume expansion including acute CHF or pulmonary edema that was verified radiographically and by physical examination. Patients who had a plasma NT-proBNP level measured at admission and a repeat measurement 2-12 hours after HD were included in this study. Over the three-year period, 36 patients with ESKD and five patients with AKI requiring HD fulfilled the inclusion criteria.
resultsVolume removal via HD had no impact on NT-proBNP levels in ESKD or AKI patients (ESKD p=0.7858 and AKI p=0.6903). Our patients exhibited markedly elevated NT-proBNP due to volume expansion and renal dysfunction. During the study period, 30% of the patients with ESKD (11/36) died.
conclusionVolume expansion is the main factor causing elevated NT-proBNP levels in acute or chronic HD patients. Reducing predialysis volume expansion with a single hemodialysis session has no impact on NT-proBNP level. Therefore, repeating the NT-proBNP level post-HD has no clinical value. Our data suggest that NT-proBNP is a useful cardiac biomarker for volume expansion, and its elevated level predicts high cardiovascular mortality and recurrent hospitalizations in acute and chronic HD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.